RxDoctor Payments Data

Robert Schmidt, MD

Family Medicine · St Marys, PANPI 1780688481

Payments from drug & device makers

$17,417in general payments, 2019–2025

Across 248 payments — averaging $70.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$15K
  • AstraZeneca$490
  • Novo Nordisk$451
  • GSK$425
  • Johnson & Johnson$289
  • Pfizer$179
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$1,4008%
  • Speaking & faculty fees$12,20070%
  • Travel & lodging$1571%
  • Food & beverage$3,60221%
  • Education$570%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,417 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$110,146
Medicare patients
298
Services billed
1,293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin117$129,970
EliquisApixaban123$118,040
OzempicSemaglutide79$93,485
TrulicityDulaglutide71$72,170
Repatha SureclickEvolocumab83$66,606
XareltoRivaroxaban48$50,098
FarxigaDapagliflozin Propanediol55$48,206
MounjaroTirzepatide41$43,731
OxycontinOxycodone Hcl24$33,026
NucyntaTapentadol Hcl25$28,771
RybelsusSemaglutide19$19,296
TradjentaLinagliptin11$15,865
InvokanaCanagliflozin14$14,195
Lantus SolostarInsulin Glargine,hum.Rec.Anlog96$14,070
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$12,448

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$55$145,835128 claims
PfizerEliquis$179$118,040123 claims
Lilly USA, LLCTrulicity, Mounjaro$43$115,901112 claims
Novo NordiskOzempic, Rybelsus$451$112,78198 claims
Johnson & JohnsonXarelto, Invokana$289$64,29362 claims
AstraZenecaFarxiga, Breztri Aerosphere$490$55,77967 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in St Marys

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →